NOVEN TO PRESENT DATA FOR: EXTRAPOLATING PEDIATRIC TRANSDERMAL ADHD TREATMENT EFFICACY DATA TO ADULT POPULATIONS AND CORRELATING TREATMENT EFFECT DURATION WITH PATCH WEAR TIMES AT AMERICAN PSYCHIATRIC NURSES ASSOCIATION ANNUAL CONFERENCE
prnewswire.com
news
2022-10-17 13:03:00

–First study extrapolates efficacy of transdermal dextroamphetamine from pediatric to adult populations– 
–Second study explores variations in patch wear-times–
MIAMI and JERSEY CITY, N.J., Oct. 17, 2022 /PRNewswire/ -- Noven Pharmaceuticals. Inc., (Noven), a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. focusing on the development of transdermal therapy, announced today it will present the results of two pharmacokinetic (PK) modeling datasets at the 36th American Psychiatric Nurses Association (APNA) annual conference in Long Beach, California October 19-22, 2022.
